foxo4-dri senolytic peptide 2024 2023 study Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells Senotherapy for chronic lung disease – foxo4-dri senolytic 2024 FOXO4-DRI: Human

INFOGRAPHIC BRIEFS Infographic Brief 1 Placement: After ## How GHK-Cu Is Thought to Work Title: GHK-Cu Mechanism and Skin Biology Pathways Purpose: Explain how GHK-Cu is discussed in relation to copper binding, fibroblast activity, collagen synthesis, extracellular matrix remodeling, inflammation, and wound repair mechanisms

REDEFINE 1 -- CagriSema phase 3 (Aronne et al., 2025): CagriSema 2.4/2.4 mg produced 22.7% mean weight loss at 68 weeks vs 2.1% placebo

Findings from research models do not establish safety or efficacy in humans

Separate vials are more work but let you titrate each compound on its own schedule

This testing approach helps support consistency, transparency, and reliable documentation across research peptide vials, peptide capsules, liquid peptide sprays, and research compound formulations